Denne side blev automatisk oversat, og nøjagtigheden af oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Fluorouracil, Gemcitabin og strålebehandling til behandling af patienter med kræft i bugspytkirtlen

18. november 2013 opdateret af: Radiation Therapy Oncology Group

Et fase III-studie af præ- og postkemoradiation 5-FU vs. præ- og postkemoradiation gemcitabin til postoperativ adjuverende behandling af resekeret pancreasadenokarcinom

RATIONALE: Lægemidler, der bruges i kemoterapi, bruger forskellige måder til at forhindre tumorceller i at dele sig, så de holder op med at vokse eller dør. Strålebehandling bruger højenergi røntgenstråler til at beskadige tumorceller. Kombination af strålebehandling med kemoterapi kan dræbe flere tumorceller. Det vides endnu ikke, hvilket behandlingsregime der er mest effektivt til kræft i bugspytkirtlen.

FORMÅL: Randomiseret fase III-forsøg til at sammenligne effektiviteten af fluorouracil og gemcitabin plus strålebehandling til behandling af patienter med kræft i bugspytkirtlen, som er blevet opereret.

Studieoversigt

Status

Afsluttet

Betingelser

Kræft i bugspytkirtlen

Intervention / Behandling

Detaljeret beskrivelse

MÅL:

Sammenlign den overordnede og sygdomsfrie overlevelse af patienter med resekeret adenocarcinom i bugspytkirtlen behandlet med adjuverende fluorouracil-baseret kemoradioterapi efterfulgt af fluorouracil vs gemcitabin.
Sammenlign lokal-regional og fjern sygdomskontrol hos patienter behandlet med disse regimer.
Sammenlign de akutte og sene toksiske virkninger af disse regimer hos disse patienter.

OVERSIGT: Dette er en randomiseret, multicenter undersøgelse. Patienterne stratificeres efter nodal involvering (ja vs nej), tumordiameter (mindre end 3 cm vs 3 cm eller mere) og kirurgiske marginer (negativ vs positiv vs ukendt). Patienterne randomiseres til en af to behandlingsarme.

Arm I: Begyndende 3-8 uger efter endelig kirurgisk resektion får patienterne fluorouracil IV kontinuerligt i 3 uger. Begyndende 1-2 uger senere får patienterne fluorouracil IV kontinuerligt samtidig med strålebehandling 5 dage om ugen i 5,5 uger. Begyndende 3-5 uger efter afslutning af kemoradioterapi får patienterne fluorouracil IV kontinuerligt i 4 uger hver 6. uge i 2 forløb.
Arm II: Begyndende 3-8 uger efter endelig kirurgisk resektion får patienterne gemcitabin IV én gang ugentligt i 3 uger. Begyndende 1-2 uger senere modtager patienter kemoradioterapi som i arm I. Begyndende 3-5 uger efter afslutning af kemoradioterapi får patienterne gemcitabin IV én gang ugentligt i 3 uger hver 4. uge i 3 forløb.

Patienterne følges hver 3. måned i 1 år, hver 6. måned i 2 år og derefter årligt.

PROJEKTERET TILSLUTNING: I alt 518 patienter vil blive akkumuleret til denne undersøgelse inden for 8,6 år.

Undersøgelsestype

Interventionel

Tilmelding (Forventet)

518

Fase

Fase 3

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

Canada
- British Columbia
  - Vancouver, British Columbia, Canada, V5Z 4E6
    - British Columbia Cancer Agency
Forenede Stater
- Alabama
  - Birmingham, Alabama, Forenede Stater, 35294-3300
    - University of Alabama at Birmingham Comprehensive Cancer Center
  - Mobile, Alabama, Forenede Stater, 36688
    - MBCCOP - Gulf Coast
- Arizona
  - Phoenix, Arizona, Forenede Stater, 85006-2726
    - CCOP - Greater Phoenix
  - Phoenix, Arizona, Forenede Stater, 85012
    - Veterans Affairs Medical Center - Phoenix (Carl T. Hayden)
  - Tucson, Arizona, Forenede Stater, 85724
    - Arizona Cancer Center
  - Tucson, Arizona, Forenede Stater, 85723
    - Veterans Affairs Medical Center - Tucson
- Arkansas
  - Little Rock, Arkansas, Forenede Stater, 72205
    - University of Arkansas for Medical Sciences
  - Little Rock, Arkansas, Forenede Stater, 72205
    - Veterans Affairs Medical Center - Little Rock (McClellan)
- California
  - Duarte, California, Forenede Stater, 91010
    - City of Hope Comprehensive Cancer Center
  - Los Angeles, California, Forenede Stater, 90095-1781
    - Jonsson Comprehensive Cancer Center, UCLA
  - Los Angeles, California, Forenede Stater, 90033-0804
    - USC/Norris Comprehensive Cancer Center and Hospital
  - Los Angeles, California, Forenede Stater, 90073
    - Veterans Affairs Medical Center - West Los Angeles
  - Martinez, California, Forenede Stater, 94553
    - Veterans Affairs Outpatient Clinic - Martinez
  - Oakland, California, Forenede Stater, 94609-3305
    - CCOP - Bay Area Tumor Institute
  - Orange, California, Forenede Stater, 92868
    - Chao Family Comprehensive Cancer Center
  - Sacramento, California, Forenede Stater, 95817
    - University of California Davis Medical Center
  - San Francisco, California, Forenede Stater, 94121
    - Veterans Affairs Medical Center - San Francisco
  - Santa Rosa, California, Forenede Stater, 95403
    - CCOP - Santa Rosa Memorial Hospital
  - Travis Air Force Base, California, Forenede Stater, 94535
    - David Grant Medical Center
- Colorado
  - Denver, Colorado, Forenede Stater, 80220
    - Veterans Affairs Medical Center - Denver
  - Denver, Colorado, Forenede Stater, 80010
    - University of Colorado Cancer Center
- District of Columbia
  - Washington, District of Columbia, Forenede Stater, 20060
    - MBCCOP - Howard University Cancer Center
- Florida
  - Jacksonville, Florida, Forenede Stater, 32224
    - Mayo Clinic
- Georgia
  - Atlanta, Georgia, Forenede Stater, 30342-1701
    - CCOP - Atlanta Regional
  - Fort Gordon, Georgia, Forenede Stater, 30905-5650
    - Dwight David Eisenhower Army Medical Center
- Hawaii
  - Honolulu, Hawaii, Forenede Stater, 96859-5000
    - Tripler Army Medical Center
  - Honolulu, Hawaii, Forenede Stater, 96813-2424
    - Cancer Research Center of Hawaii
- Illinois
  - Chicago, Illinois, Forenede Stater, 60612-7323
    - MBCCOP - University of Illinois at Chicago
  - Chicago, Illinois, Forenede Stater, 60612
    - Veterans Affairs Medical Center - Chicago (Westside Hospital)
  - Chicago, Illinois, Forenede Stater, 60611-3013
    - Robert H. Lurie Comprehensive Cancer Center, Northwestern University
  - Decatur, Illinois, Forenede Stater, 62526
    - CCOP - Central Illinois
  - Hines, Illinois, Forenede Stater, 60141
    - Veterans Affairs Medical Center - Hines (Hines Junior VA Hospital)
  - Maywood, Illinois, Forenede Stater, 60153-5500
    - Loyola University Medical Center
- Kansas
  - Kansas City, Kansas, Forenede Stater, 66160-7353
    - University of Kansas Medical Center
  - Wichita, Kansas, Forenede Stater, 67214-3882
    - CCOP - Wichita
  - Wichita, Kansas, Forenede Stater, 67218
    - Veterans Affairs Medical Center - Wichita
- Kentucky
  - Lexington, Kentucky, Forenede Stater, 40536-0084
    - Albert B. Chandler Medical Center, University of Kentucky
  - Lexington, Kentucky, Forenede Stater, 40502-2236
    - Veterans Affairs Medical Center - Lexington
- Louisiana
  - New Orleans, Louisiana, Forenede Stater, 70112
    - Tulane University School of Medicine
  - New Orleans, Louisiana, Forenede Stater, 70112
    - MBCCOP - LSU Medical Center
  - New Orleans, Louisiana, Forenede Stater, 70112
    - Veterans Affairs Medical Center - New Orleans
  - Shreveport, Louisiana, Forenede Stater, 71130-3932
    - Louisiana State University Health Sciences Center - Shreveport
  - Shreveport, Louisiana, Forenede Stater, 71130
    - Veterans Affairs Medical Center - Shreveport
- Massachusetts
  - Boston, Massachusetts, Forenede Stater, 02118
    - Boston Medical Center
  - Jamaica Plain, Massachusetts, Forenede Stater, 02130
    - Veterans Affairs Medical Center - Boston (Jamaica Plain)
- Michigan
  - Ann Arbor, Michigan, Forenede Stater, 48105
    - Veterans Affairs Medical Center - Ann Arbor
  - Ann Arbor, Michigan, Forenede Stater, 48106
    - CCOP - Ann Arbor Regional
  - Ann Arbor, Michigan, Forenede Stater, 48109-0912
    - University Of Michigan Comprehensive Cancer Center
  - Detroit, Michigan, Forenede Stater, 48202
    - Henry Ford Hospital
  - Detroit, Michigan, Forenede Stater, 48201-1379
    - Barbara Ann Karmanos Cancer Institute
  - Detroit, Michigan, Forenede Stater, 48201-1932
    - Veterans Affairs Medical Center - Detroit
  - Royal Oak, Michigan, Forenede Stater, 48073-6769
    - CCOP - Beaumont
  - Southfield, Michigan, Forenede Stater, 48075-9975
    - Providence Hospital - Southfield
- Minnesota
  - Duluth, Minnesota, Forenede Stater, 55805
    - CCOP - Duluth
- Mississippi
  - Biloxi, Mississippi, Forenede Stater, 39531-2410
    - Veterans Affairs Medical Center - Biloxi
  - Jackson, Mississippi, Forenede Stater, 39216-4505
    - University of Mississippi Medical Center
  - Jackson, Mississippi, Forenede Stater, 39216
    - Veterans Affairs Medical Center - Jackson
  - Keesler AFB, Mississippi, Forenede Stater, 39534-2576
    - Keesler Medical Center - Keesler AFB
- Missouri
  - Kansas City, Missouri, Forenede Stater, 64128
    - Veterans Affairs Medical Center - Kansas City
  - Kansas City, Missouri, Forenede Stater, 64131
    - CCOP - Kansas City
  - Saint Louis, Missouri, Forenede Stater, 63141
    - CCOP - St. Louis-Cape Girardeau
  - Saint Louis, Missouri, Forenede Stater, 63110
    - St. Louis University Health Sciences Center
  - Springfield, Missouri, Forenede Stater, 65807
    - CCOP - Cancer Research for the Ozarks
- Montana
  - Billings, Montana, Forenede Stater, 59101
    - CCOP - Montana Cancer Consortium
- New Mexico
  - Albuquerque, New Mexico, Forenede Stater, 87108-5138
    - Veterans Affairs Medical Center - Albuquerque
  - Albuquerque, New Mexico, Forenede Stater, 87131
    - MBCCOP - University of New Mexico HSC
- New York
  - Albany, New York, Forenede Stater, 12208
    - Veterans Affairs Medical Center - Albany
  - Buffalo, New York, Forenede Stater, 14220
    - Western New York Urology Associates
  - New York, New York, Forenede Stater, 10011
    - St. Vincents Comprehensive Cancer Center
  - New York, New York, Forenede Stater, 10032
    - Herbert Irving Comprehensive Cancer Center
  - Rochester, New York, Forenede Stater, 14642
    - University of Rochester Medical Center
- North Carolina
  - Winston-Salem, North Carolina, Forenede Stater, 27104-4241
    - CCOP - Southeast Cancer Control Consortium
- Ohio
  - Cincinnati, Ohio, Forenede Stater, 45220-2288
    - Veterans Affairs Medical Center - Cincinnati
  - Cincinnati, Ohio, Forenede Stater, 45267-0501
    - Barrett Cancer Center
  - Cleveland, Ohio, Forenede Stater, 44195-9001
    - Cleveland Clinic Taussig Cancer Center
  - Columbus, Ohio, Forenede Stater, 43210-1240
    - Arthur G. James Cancer Hospital - Ohio State University
  - Columbus, Ohio, Forenede Stater, 43206
    - CCOP - Columbus
  - Dayton, Ohio, Forenede Stater, 45428
    - Veterans Affairs Medical Center - Dayton
  - Kettering, Ohio, Forenede Stater, 45429
    - CCOP - Dayton
- Oklahoma
  - Oklahoma City, Oklahoma, Forenede Stater, 73104
    - Oklahoma Medical Research Foundation
  - Oklahoma City, Oklahoma, Forenede Stater, 73104
    - Veterans Affairs Medical Center - Oklahoma City
- Oregon
  - Portland, Oregon, Forenede Stater, 97207
    - Veterans Affairs Medical Center - Portland
  - Portland, Oregon, Forenede Stater, 97225
    - CCOP - Columbia River Program
  - Portland, Oregon, Forenede Stater, 97239
    - Oregon Cancer Institute
- South Carolina
  - Charleston, South Carolina, Forenede Stater, 29425-0721
    - Medical University of South Carolina
  - Charleston, South Carolina, Forenede Stater, 29401-5799
    - Veterans Affairs Medical Center - Charleston
  - Greenville, South Carolina, Forenede Stater, 29615
    - CCOP - Greenville
  - Spartanburg, South Carolina, Forenede Stater, 29303
    - CCOP - Upstate Carolina
- Texas
  - Fort Sam Houston, Texas, Forenede Stater, 78234-6200
    - Brooke Army Medical Center
  - Galveston, Texas, Forenede Stater, 77555-0565
    - University of Texas Medical Branch
  - Houston, Texas, Forenede Stater, 77030
    - Baylor College of Medicine
  - Houston, Texas, Forenede Stater, 77030
    - Veterans Affairs Medical Center - Houston
  - Houston, Texas, Forenede Stater, 77030-4095
    - University of Texas - MD Anderson Cancer Center
  - Lubbock, Texas, Forenede Stater, 79415
    - Texas Tech University Health Science Center
  - San Antonio, Texas, Forenede Stater, 78284
    - Veterans Affairs Medical Center - San Antonio (Murphy)
  - San Antonio, Texas, Forenede Stater, 78284-7845
    - University of Texas Health Science Center at San Antonio
  - Temple, Texas, Forenede Stater, 76504
    - Veterans Affairs Medical Center - Temple
  - Temple, Texas, Forenede Stater, 76508
    - CCOP - Scott and White Hospital
- Utah
  - Salt Lake City, Utah, Forenede Stater, 84148
    - Veterans Affairs Medical Center - Salt Lake City
  - Salt Lake City, Utah, Forenede Stater, 84112-5550
    - Huntsman Cancer Institute
- Virginia
  - Norfolk, Virginia, Forenede Stater, 23510-1115
    - Eastern Virginia Medical School
- Washington
  - Seattle, Washington, Forenede Stater, 98101
    - CCOP - Virginia Mason Research Center
  - Seattle, Washington, Forenede Stater, 98104
    - Swedish Cancer Institute
  - Seattle, Washington, Forenede Stater, 98108
    - Veterans Affairs Medical Center - Seattle
  - Tacoma, Washington, Forenede Stater, 98431-5000
    - Madigan Army Medical Center
  - Tacoma, Washington, Forenede Stater, 98405-0986
    - CCOP - Northwest

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

SYGDOMS KARAKTERISTIKA:

Histologisk bekræftet adenocarcinom i bugspytkirtlen
- Trin T1-4, N0-1 (stadie I-IVA)
- Ingen M1 eller NX iscenesættelse
- Primær tumor i bugspytkirtlen (pancreas hoved, hals, ucineret proces eller krop/hale) og maksimal diameter/dimension og tumorstatus ved kirurgisk margin kendt
Forudgående potentielt helbredende grov resektion inden for 3-8 uger før undersøgelse
Ingen non-adenocarcinomer, adenosquamøse carcinomer, øcellecarcinomer, cystadenomer, cystadenocarcinomer, carcinoide tumorer, duodenale carcinomer, distalt galdevejscarcinom eller ampulær carcinom
Ingen tilbagevendende sygdom
Post-resektion CA-19-9 niveau påkrævet

PATIENT KARAKTERISTIKA:

Alder:

18 og derover

Ydeevnestatus:

Karnofsky 60-100 %

Forventede levealder:

Ikke specificeret

Hæmatopoietisk:

WBC mindst 3.000/mm^3
Blodpladetal mindst 100.000/mm^3

Hepatisk:

Bilirubin ikke større end 1,5 gange øvre normalgrænse (ULN)
SGOT ikke større end 5 gange ULN

Nyre:

Kreatinin ikke større end 1,5 gange ULN

Andet:

Ingen væsentlig kvalme eller opkastning
Ingen tidligere malignitet inden for de seneste 5 år undtagen ikke-melanomatøs hudkræft eller carcinom in situ i livmoderhalsen
I stand til at opretholde tilstrækkelig ernæring (mindst 1.500 kalorier/dag)
- Ernæringssonde tilladt
Ikke gravid
Negativ graviditetstest
Fertile patienter skal bruge effektiv prævention

FORUDSÆTNING SAMTYDLIG TERAPI:

Biologisk terapi:

Ikke specificeret

Kemoterapi:

Ingen forudgående kemoterapi

Endokrin terapi:

Ikke specificeret

Strålebehandling:

Ingen forudgående strålebehandling

Kirurgi:

Se Sygdomskarakteristika

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

Primært formål: Behandling
Tildeling: Randomiseret

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Radiation Therapy Oncology Group

Samarbejdspartnere

National Cancer Institute (NCI)

Eastern Cooperative Oncology Group

Southwest Oncology Group

Efterforskere

Studiestol: William F. Regine, MD, Lucille P. Markey Cancer Center at University of Kentucky

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Generelle publikationer

Abrams RA, Winter KA, Regine WF, Safran H, Hoffman JP, Lustig R, Konski AA, Benson AB, Macdonald JS, Rich TA, Willett CG. Failure to adhere to protocol specified radiation therapy guidelines was associated with decreased survival in RTOG 9704--a phase III trial of adjuvant chemotherapy and chemoradiotherapy for patients with resected adenocarcinoma of the pancreas. Int J Radiat Oncol Biol Phys. 2012 Feb 1;82(2):809-16. doi: 10.1016/j.ijrobp.2010.11.039. Epub 2011 Feb 1.
Berger AC, Winter K, Hoffman JP, Regine WF, Abrams RA, Safran H, Freedman GM, Benson AB 3rd, Macdonald J, Willett CG. Five year results of US intergroup/RTOG 9704 with postoperative CA 19-9 </=90 U/mL and comparison to the CONKO-001 trial. Int J Radiat Oncol Biol Phys. 2012 Nov 1;84(3):e291-7. doi: 10.1016/j.ijrobp.2012.04.035. Epub 2012 Jun 9.
Farrell JJ, Bae K, Wong J, Guha C, Dicker AP, Elsaleh H. Cytidine deaminase single-nucleotide polymorphism is predictive of toxicity from gemcitabine in patients with pancreatic cancer: RTOG 9704. Pharmacogenomics J. 2012 Oct;12(5):395-403. doi: 10.1038/tpj.2011.22. Epub 2011 May 31.
Regine WF, Winter KA, Abrams R, Safran H, Hoffman JP, Konski A, Benson AB, Macdonald JS, Rich TA, Willett CG. Fluorouracil-based chemoradiation with either gemcitabine or fluorouracil chemotherapy after resection of pancreatic adenocarcinoma: 5-year analysis of the U.S. Intergroup/RTOG 9704 phase III trial. Ann Surg Oncol. 2011 May;18(5):1319-26. doi: 10.1245/s10434-011-1630-6. Epub 2011 Mar 10.
Showalter TN, Winter KA, Berger AC, Regine WF, Abrams RA, Safran H, Hoffman JP, Benson AB, MacDonald JS, Willett CG. The influence of total nodes examined, number of positive nodes, and lymph node ratio on survival after surgical resection and adjuvant chemoradiation for pancreatic cancer: a secondary analysis of RTOG 9704. Int J Radiat Oncol Biol Phys. 2011 Dec 1;81(5):1328-35. doi: 10.1016/j.ijrobp.2010.07.1993. Epub 2010 Oct 8.
Tempero MA, Winter KA, Kim GE, et al.: S100A2 as a prognostic marker in patients receiving adjuvant therapy for pancreatic cancer (PC): A secondary analysis of RTOG 9704. [Abstract] J Clin Oncol 29 (Suppl 15): A-4118, 2011.
Farrell J, Bae K, Guha C, et al.: Correlation of cytidine deaminase single nucleotide polymorphism and toxicity from gemcitabine in patients with pancreatic cancer from RTOG 9704. [Abstract] American Society of Clinical Oncology 2009 Gastrointestinal Cancers Symposium, 15-17 January 2009, San Francisco, CA. A-115, 2009.
Farrell JJ, Elsaleh H, Garcia M, Lai R, Ammar A, Regine WF, Abrams R, Benson AB, Macdonald J, Cass CE, Dicker AP, Mackey JR. Human equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancer. Gastroenterology. 2009 Jan;136(1):187-95. doi: 10.1053/j.gastro.2008.09.067. Epub 2008 Oct 7.
Piperdi B, Ng S, Piperdi M, et al.: Single institutional experience with oral capecitabine (Cap) in adjuvant therapy for pancreatic cancer: Gemcitabine (G) followed by Cap/RT followed by G. [Abstract] American Society of Clinical Oncology 2009 Gastrointestinal Cancers Symposium, 15-17 January 2009, San Francisco, CA. A-229, 2009.
Berger AC, Garcia M Jr, Hoffman JP, Regine WF, Abrams RA, Safran H, Konski A, Benson AB 3rd, MacDonald J, Willett CG. Postresection CA 19-9 predicts overall survival in patients with pancreatic cancer treated with adjuvant chemoradiation: a prospective validation by RTOG 9704. J Clin Oncol. 2008 Dec 20;26(36):5918-22. doi: 10.1200/JCO.2008.18.6288. Epub 2008 Nov 24.
Regine WF, Winter KA, Abrams RA, Safran H, Hoffman JP, Konski A, Benson AB, Macdonald JS, Kudrimoti MR, Fromm ML, Haddock MG, Schaefer P, Willett CG, Rich TA. Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial. JAMA. 2008 Mar 5;299(9):1019-26. doi: 10.1001/jama.299.9.1019. Erratum In: JAMA. 2008 Apr 23/30;299(16):1902.
Abrams RA, Winter KA, Regine WF, et al.: Correlation of RTOG 9704 (adjuvant therapy (rx) of pancreatic adenocarcinoma (pan ca)) radiation therapy quality assurance scores (RTQASc) with survival (S). [Abstract] J Clin Oncol 25 (Suppl 18): A-4523, 2007.
Berger AC, Winter K, Hoffman J, et al.: Post-resection CA 19-9 predicts overall survival (OS) in patients treated with adjuvant chemoradiation: a secondary endpoint of RTOG 9704. [Abstract] J Clin Oncol 25 (Suppl 18): A-4522, 2007.
Regine WF, Garcia M, Berger AC, et al.: Post-resectional CA 19-9 values >90 are associated with significantly worse survival in patients with pancreatic carcinoma treated with adjuvant therapy on RTOG 9704: implications for current and future trials. [Abstract] Int J Radiat Oncol Biol Phys 69 (3 Suppl): A-137, S78, 2007.
Abrams RA, Winter KA, Regine WF, et al.: RTOG 9704: radiotherapy quality assurance (QA) review and survival. [Abstract] Int J Radiat Oncol Biol Phys 66 (3 Suppl 1): A-39, S22, 2006.
Regine WF, Winter KA, Abrams R, et al.: A phase III intergroup trial (RTOG 97-04) of adjuvant pre and post chemoradiation (CRT) 5-FU vs. gemcitabine (G) for resected pancreatic adenocarcinoma. [Abstract] Int J Radiat Oncol Biol Phys 66 (3 Suppl 1): A-42, S23-4, 2006.
Regine WF, Winter KW, Abrams R, et al.: RTOG 9704 a phase III study of adjuvant pre and post chemoradiation (CRT) 5-FU vs. gemcitabine (G) for resected pancreatic adenocarcinoma. [Abstract] J Clin Oncol 24 (Suppl 18): A-4007, 180s, 2006.
Reyngold M, Winter KA, Regine WF, Abrams RA, Safran H, Hoffman JP, Mowat RB, Hayes JP, Kessel IL, DiPetrillo T, Narayan S, Chen Y, Ben-Josef E, Delouya G, Suh JH, Meyer J, Haddock MG, Feldman M, Gaur R, Yost K, Peterson RA, Sherr DL, Moughan J, Crane CH. Marital Status and Overall Survival in Patients with Resectable Pancreatic Cancer: Results of an Ancillary Analysis of NRG Oncology/RTOG 9704. Oncologist. 2020 Mar;25(3):e477-e483. doi: 10.1634/theoncologist.2019-0562. Epub 2019 Dec 16.
Lawrence YR, Moughan J, Magliocco AM, Klimowicz AC, Regine WF, Mowat RB, DiPetrillo TA, Small W Jr, Simko JP, Golan T, Winter KA, Guha C, Crane CH, Dicker AP. Expression of the DNA repair gene MLH1 correlates with survival in patients who have resected pancreatic cancer and have received adjuvant chemoradiation: NRG Oncology RTOG Study 9704. Cancer. 2018 Feb 1;124(3):491-498. doi: 10.1002/cncr.31058. Epub 2017 Oct 20.

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart

1. juli 1998

Primær færdiggørelse (Faktiske)

1. oktober 2005

Datoer for studieregistrering

Først indsendt

1. november 1999

Først indsendt, der opfyldte QC-kriterier

26. januar 2003

Først opslået (Skøn)

27. januar 2003

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Skøn)

19. november 2013

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

18. november 2013

Sidst verificeret

1. november 2013

Mere information

Begreber relateret til denne undersøgelse

Nøgleord

Yderligere relevante MeSH-vilkår

Andre undersøgelses-id-numre

RTOG-9704
CDR0000066076
E-R9704
SWOG-R9704

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .